EA200001050A1 - Малеат пароксетина - Google Patents

Малеат пароксетина

Info

Publication number
EA200001050A1
EA200001050A1 EA200001050A EA200001050A EA200001050A1 EA 200001050 A1 EA200001050 A1 EA 200001050A1 EA 200001050 A EA200001050 A EA 200001050A EA 200001050 A EA200001050 A EA 200001050A EA 200001050 A1 EA200001050 A1 EA 200001050A1
Authority
EA
Eurasian Patent Office
Prior art keywords
paroxethine
maleat
depression
prevention
preparation
Prior art date
Application number
EA200001050A
Other languages
English (en)
Inventor
Виктор Витольд Яцевич
Алан Дэвид Джоунс
Джон Мэн
Original Assignee
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807627.6A external-priority patent/GB9807627D0/en
Priority claimed from GBGB9823856.1A external-priority patent/GB9823856D0/en
Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс
Publication of EA200001050A1 publication Critical patent/EA200001050A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описывается малеат пароксетина, его получение и применение для лечения и профилактики, inter alia, депрессии.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200001050A 1998-04-09 1999-04-09 Малеат пароксетина EA200001050A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9807627.6A GB9807627D0 (en) 1998-04-09 1998-04-09 Novel compounds
GBGB9823856.1A GB9823856D0 (en) 1998-10-30 1998-10-30 Novel compound
PCT/GB1999/001106 WO1999052901A1 (en) 1998-04-09 1999-04-09 Paroxetine maleate

Publications (1)

Publication Number Publication Date
EA200001050A1 true EA200001050A1 (ru) 2001-04-23

Family

ID=26313449

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001050A EA200001050A1 (ru) 1998-04-09 1999-04-09 Малеат пароксетина

Country Status (18)

Country Link
EP (1) EP1073652A1 (ru)
JP (1) JP2002511466A (ru)
KR (1) KR20010042552A (ru)
CN (1) CN1305474A (ru)
AP (1) AP2000001950A0 (ru)
AU (1) AU3433499A (ru)
BG (1) BG104914A (ru)
BR (1) BR9909529A (ru)
CA (1) CA2327450A1 (ru)
EA (1) EA200001050A1 (ru)
HU (1) HUP0103651A3 (ru)
ID (1) ID26879A (ru)
IL (1) IL138920A0 (ru)
NO (1) NO20005037L (ru)
PL (1) PL343378A1 (ru)
SK (1) SK15032000A3 (ru)
TR (1) TR200002939T2 (ru)
WO (1) WO1999052901A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
NL1017421C2 (nl) 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
ITTO20060143A1 (it) * 2006-02-28 2007-09-01 Bridgestone Corp Pneumatico

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DK0994872T3 (da) * 1997-06-10 2001-05-28 Synthon Bv 4-phenylpiperidin-forbindelser

Also Published As

Publication number Publication date
JP2002511466A (ja) 2002-04-16
SK15032000A3 (sk) 2001-04-09
HUP0103651A3 (en) 2002-12-28
BG104914A (en) 2001-10-31
PL343378A1 (en) 2001-08-13
HUP0103651A2 (en) 2002-08-28
AU3433499A (en) 1999-11-01
BR9909529A (pt) 2000-12-12
NO20005037L (no) 2000-12-05
CN1305474A (zh) 2001-07-25
CA2327450A1 (en) 1999-10-21
ID26879A (id) 2001-02-15
EP1073652A1 (en) 2001-02-07
NO20005037D0 (no) 2000-10-06
KR20010042552A (ko) 2001-05-25
WO1999052901A1 (en) 1999-10-21
TR200002939T2 (tr) 2001-02-21
AP2000001950A0 (en) 2000-12-31
IL138920A0 (en) 2001-11-25

Similar Documents

Publication Publication Date Title
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA199800733A1 (ru) Антагонисты рецептора il-8
DE69907977D1 (de) Pyrrolobenzodiazepine
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
EA199800913A1 (ru) Кальцилитические соединения
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
EA200100688A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОБИЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
EA199900620A1 (ru) Фталазиноны
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
DE60041761D1 (de) Tribonektine
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
EA199900381A1 (ru) Арил(тио)эфиры галогенпиримидина в качестве пестицидов
EA200401054A1 (ru) Производные n-бифенилметиламиноциклоалканкарбоксамида с заместителем на метиле, в качестве антагонистов брадикинина
EA200201214A1 (ru) Замещенные тиоацетамиды
EA200400586A1 (ru) Замещённые тиоацетамиды
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
DE60139466D1 (de) Behandlung von diabetes
EA200001050A1 (ru) Малеат пароксетина
EA200200381A1 (ru) Тетрагидротиопиранфталазиноновые производные в качестве ингибиторов pde4
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
EA200200091A1 (ru) Содержащая амброксол пастилка
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
EA200200798A1 (ru) Кальцилитические соединения
EA199900241A1 (ru) ЗАМЕЩЕННЫЕ 1,2,3,4-ТЕТРАГИДРО-2-ДИБЕНЗОФУРАНАМИНЫ И 2-АМИНОЦИКЛОГЕПТА [b] БЕНЗОФУРАНЫ